Abstract
Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Infectious Disorders - Drug Targets
Title: Management of Tuberculosis in Children and New Treatment Options
Volume: 11 Issue: 2
Author(s): B. J. Marais, H. S. Schaaf and P. R. Donald
Affiliation:
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Abstract: Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Export Options
About this article
Cite this article as:
J. Marais B., S. Schaaf H. and R. Donald P., Management of Tuberculosis in Children and New Treatment Options, Infectious Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152611795589645
DOI https://dx.doi.org/10.2174/187152611795589645 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Design, Network Analysis, In silico Modeling and Synthesis of Biologically Active Thiazolo Quinazoline Scaffolds as Anti-tubercular Agent
Current Chemical Biology Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine The Manzamines as an Example of the Unique Structural Classes Available for the Discovery and Optimization of Infectious Disease Controls Based on Marine Natural Products
Current Pharmaceutical Design Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Inflammation in Fish As Seen from A Morphological Point of View with Special Reference to the Vascular Compartment
Current Pharmaceutical Design Prediction of Cytochrome 450 Mediated Drug-Drug Interactions by Three-Dimensional Cultured Hepatocytes
Mini-Reviews in Medicinal Chemistry The Long Pentraxin PTX3, a Soluble Pattern Recognition Receptor Involved in Innate Immunity,Inflammation and Female Fertility
Current Immunology Reviews (Discontinued) Sequence-Structure Similarity: Do Sequentially Identical Peptide Fragments have Similar Three-Dimensional Structures?
Current Bioinformatics Subject Index To Volume 7
Current Drug Targets Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review
Cardiovascular & Hematological Disorders-Drug Targets 1,2,3-Triazole-Isoxazole Based Acetylcholinesterase Inhibitors: Synthesis, Biological Evaluation and Docking Study
Letters in Drug Design & Discovery The Role of Autophagy in Rheumatic Disease
Current Drug Targets Antimycobacterial Agents: Synthesis and Biological Evaluation of Novel 4-(Substituted-phenyl)-6-methyl-2-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine- 5-carboxamide Derivatives by Using One-pot Multicomponent Method
Letters in Drug Design & Discovery Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) Review of Common Sequence Alignment Methods: Clues to Enhance Reliability
Current Genomics MRSA Infections: From Classical Treatment to Suicide Drugs
Current Medicinal Chemistry Uncovering Drug Mechanism of Action by Proteome Wide- Identification of Drug-Binding Proteins
Medicinal Chemistry Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry Antibacterial Effects of Carbon Monoxide
Current Pharmaceutical Biotechnology